Vol. 34 No. 3 (2019): Revista Uruguaya de Cardiología
Artículos de revisión

The best of the 2019 European Society of Cardiology Congress

  • Dr. Juan Pablo Bachini,
  • Dr. Sebastián Lorenzo,
  • Dr. Carlos Guamán,
  • Dr. Sofía Noria,
  • Dr. Yamel Ache,
Dr. Juan Pablo Bachini
Médica Uruguaya, Instituto de Cardiología Integral. Montevideo, Uruguay
Dr. Sebastián Lorenzo
Centro Cardiovascular Casa de Galicia. Montevideo, Uruguay
Dr. Carlos Guamán
Centro Cardiovascular Universitario, Hospital de Clínicas. Montevideo, Uruguay
Dr. Sofía Noria
Editora adjunta de Revista Uruguaya de Cardiología
Dr. Yamel Ache
Centro Cardiológico Americano. Montevideo, Uruguay
Published 25-11-2019

Keywords:

CONGRESSES, HEART FAILURE, DAPAGLIFLOZIN, MYOCARDIAL REVASCULARIZATION, NEPRISILIN, ANGIOTENSINS, ATRIAL FIBRILLATION, FIBRINOLYTICS, TICAGRELOR, PRASUGREL

Abstract

The European Congress of Cardiology is one of the most relevant events of the world cardiology community. It was held from August 31 to September 4 in the heart of Paris, France, the central theme being global cardiovascular health. As usual, it was attended by more than 30,000 professionals and prominent guests. Updates of several clinical practice guides and important scientific papers were presented. These undoubtedly will impact in the treatment of patients with cardiovascular pathology.
Below we present a brief summary of some of the trials presented:

  • A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction: DAPA-HF
  • Complete revascularization with multivessel PCI for myocardial infarction: the COMPLETE Trial
  • Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction: the PARAGON-HF
  • Antithrombotic therapy for atrial fibrillation with stable coronary disease: the AFIRE Investigators
  • Ticagrelor or prasugrel in patients with acute coronary syndromes: the ISAR-REACT 5 Trial
PDF (Español (España))